Jackson v. Personal Representative of Donald Comb

District Court, D. Massachusetts·Decided August 7, 2025·No. 1:23-cv-12208·Unknown

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

CIVIL ACTION NO. 23-12208-RGS

MELISSA JACKSON and MARTA MEDA

v.

NEW ENGLAND BIOLABS, INC., PERSONAL REPRESENTATIVE OF DONALD COMB, JAMES V. ELLARD, RICHARD IRELAND, and the COMMITTEE OF NEW ENGLAND BIOLABS, INC. EMPLOYEES’ STOCK OWNERSHIP PLAN Defendants

NEW ENGLAND BIOLABS, INC. NON-VOTING STOCK OWNERSHIP PLAN Nominal Defendant

MEMORANDUM AND ORDER ON PLAINTIFFS’ MOTIONS FOR ATTORNEY FEES AND SERVICE AWARDS FOR CLASS REPRESENTATIVES

August 7, 2025 STEARNS, D.J. Before the court is plaintiffs Melissa Jackson’s and Marta Meda’s motion for attorney’s fees, costs, and expenses, as well as payment of service awards to the two class representatives. For the following reasons, the court will allow in part and deny in part the motion for attorney’s fees and expenses. It will allow in part and deny in part the motion for service awards. BACKGROUND Named plaintiffs and class representatives Jackson and Meda filed this

class action against defendants New England Biolabs, Inc. (NEB), personal representative of Donald Comb, James V. Ellard, Richard Ireland, and the Committee of New England Biolabs, Inc. Employees’ Stock Ownership Plan. Both former employees of NEB, Jackson and Meda participated in the New

England Biolabs, Inc. Non-Voting Stock Ownership Plan (the Plan) beginning in 1996 and 1986 respectively. Prior to a 2019 amendment to the Plan, participants, including former employees, were permitted to defer

distributions from their accounts until age 65. However, on August 1, 2019, NEB amended the Plan to automatically convert to cash any NEB shares allocated to former employees. On September 26, 2023, plaintiffs filed a putative class action against

NEB, alleging various violations of the Employee Retirement Income Security Act of 1974, 29 U.S.C. § 1001 et seq. (ERISA). Plaintiffs challenged the 2019 amendment and alleged that the method to establish the price paid for NEB stock in the Plan was procedurally and substantively flawed,

specifically that the valuations used to set the price paid for NEB stock in the Plan did not reflect the stock’s fair market value. See Amended Compl. (Dkt. # 31) ¶¶ 104-116. Shortly after the court on April 3, 2024, dismissed the claims challenging the 2019 amendment and allowed the claims challenging the valuation to proceed, the parties began mediation. See Dkt. # 56; Dkt. #

66. They reached a formal Settlement Agreement in April of 2025. See Dkt. # 88. The court preliminarily approved the settlement agreement on April 21, 2025, and scheduled a Fairness Hearing for August 6, 2025. See Dkt. # 94.

DISCUSSION Attorney’s Fees Plaintiffs’ counsel seeks an award of attorney’s fees equivalent to 25%

of the $7,150,000 settlement fund (approximately $1,787,500),1 as well as the reimbursement of $17,445.31 in litigation expenses and $5,356 in settlement administration expenses. See Dkt. # 97-1 at 1; Dkt. # 102 at 2. Attorneys in a certified class action may be awarded reasonable fees

and costs, subject to the discretion of the trial judge. See Fed. R. Civ. P. 23(h). In common fund cases, the trend has increasingly favored the calculation of a fee award using the percentage of the fund (POF) method (although the

1 Plaintiffs’ counsel calculated a lodestar of $733,407.50. See Dkt. # 102 at 2. They expended a total of 897.35 hours (849.80 hours from January 1, 2023 through June 26, 2025 and an additional 47.55 hours from June 27, 2025 to August 3, 2025). See Dkt. # 97-1 at 18; Dkt. # 102-1 at 2; Dkt. # 102- 2 at 2. Based on the total lodestar, their request for 25% of the Settlement Fund represents a lodestar multiplier of 2.44. See Dkt. # 102 at 2. lodestar method remains an option). See In re Thirteen Appeals Arising Out of the San Juan Dupont Plaza Hotel Fire Litig., 56 F.3d 295, 307 (1st Cir.

1995). Under the POF method, the fee award is set at a reasonable percentage of the settlement amount. The First Circuit has not recognized a particular set of factors to assess the reasonableness of a fee request. However, courts in this district have analyzed a variety of factors, including:

(1) the size of the fund created and the number of persons benefitted; (2) the presence or absence of substantial objections relative to the size of the settlement class; (3) the skill and efficiency of Class Counsel; (4) the complexity and duration of the litigation; (5) the financial risks of nonpayment taken on by Class Counsel; (6) the amount of time devoted to the case by Class Counsel; and (7) the awards in similar cases.

Ford v. Takeda Pharms. U.S.A., Inc., 2023 WL 3679031, at *1 (D. Mass. Mar. 31, 2023). The court recognizes the complexities of this litigation, the substantial benefit in both aggregate amount and on a per class member basis conferred on the members of the plaintiff class, the sophistication of ERISA litigation, the legal uncertainties, and the financial risks that plaintiffs’ counsel assumed. While the court commends plaintiffs’ counsel for the favorable result, it does believe it appropriate to adjust the fee request slightly downward. While plaintiffs’ counsel “negotiated the ability to use the discovery from the prior” New England Biolabs, Inc. v. Ralph T. Miller, 20-cv-11234 case, and relied on their prior experience in that case to benefit the class, no formal discovery occurred in this case. See Dkt. # 61-1 ¶ 5.4; Dkt. # 97-1 at 19. One

of plaintiffs’ claims challenging the validity of the 2019 amendment’s alteration of the right of former employees to remain in the ESOP (which this court dismissed) was substantially identical to the claim they had pursued in the Miller litigation. See New England Biolabs, Inc. v. Miller, 2021 WL

11702966, at *3-4 (D. Mass. May 26, 2021). Shortly after the court on April 3, 2024, dismissed that claim challenging the 2019 amendment and allowed some of the claims challenging the valuation to proceed, the parties on May

10, 2024 agreed to pursue mediation. See Dkt. # 66. The court will award a fee of 20% of the settlement fund as a reasonable percentage, translating into an award of $1,430,000. The deduction in the fee is by no means intended to signal any dissatisfaction on the part of the

court with the attorneys’ efforts to bring the case to a prompt and just conclusion. The court is modestly adjusting the fee so that the 20% of fund award better fits the effort expended in litigating the case – a conclusion that the lodestar calculation inferentially supports. Courts within this district

recognize that an award of 20% to 30% of the common fund in fees is reasonable and have awarded comparable amounts. See Bezdek v. Vibram USA Inc., 79 F. Supp. 3d 324, 349-350 (D. Mass. 2015), aff’d, 809 F.3d 78 (1st Cir. 2015); Arkansas Tchr. Ret. Sys. v. State St. Bank & Tr. Co., 512 F. Supp. 3d 196, 258 (D. Mass. 2020) (awarding attorney’s fees of 20% of the

common fund in ERISA class action); In re Ranbaxy Generic Drug Application Antitrust Litig., 630 F. Supp. 3d 241, 248 (D. Mass. 2022) (adjusting significantly downward attorney’s fees request for 27.5% of the settlement fund to 20% partly because the litigation was a successor of a civil

settlement and criminal plea agreement). Expenses “[L]awyers whose efforts succeed in creating a common fund for the

Free access — add to your briefcase to read the full text and ask questions with AI

Jackson v. Personal Representative of Donald Comb, (D. Mass. 2025).

Jackson v. Personal Representative of Donald Comb (Jackson v. Personal Representative of Donald Comb) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Weisburgh v. Fidelity Magellan Fund
167 F.3d 735 (First Circuit, 1999)
Defalco v. Vibram USA, Inc.
809 F.3d 78 (First Circuit, 2015)
Bezdek v. Vibram USA Inc.
79 F. Supp. 3d 324 (D. Massachusetts, 2015)